Patent Application
20220267852
The present invention relates to a method for specifically detecting and quantifying the SMN1 gene contained in a punched piece by direct real-time PCR using a punched piece of a certain size obtained from a dried blood spot in a filter paper and to a primer used for the method.
Spinal muscular atrophy (SMA) is a lower motor neuron disease characterized by muscular atrophy and progressive muscle weakness due to degeneration of the anterior horn cells in the spinal cord and is designated to the incurable disease. There are four types of SMA depending on the age of symptom onset and the degree. In particular, in type I with the onset within about six months after birth, the diagnosis tends to be delayed also because of the onset in the neonatal period, and the symptoms tend to become severe. Ninety percent or more of the SMA type I patients die before 2 years of age or require a ventilator for the whole life. The prevalence of type I is around one in 20000 births, which is high, and it is known that therapeutic effects are expected more as the treatment is started earlier. Thus, request for newborn screening test is next to that for primary immunodeficiencies. It is known that 95% of the SMA type I patients are caused by homozygous deletion of survival of motor neuron 1 (SMN1) gene, which plays a role of maintaining the functions of the motor neuron, and thus the gene to be screened is the SMN1 gene. However, in the SMN2 gene, which compensates the gene, the 6th nucleotide in exon 7 is T instead of C in the SMN1 gene, and thus the sequence causes skipping of exon 7 during the splicing. Therefore, the single nucleotide polymorphism is preferably used as the specific target. In a method for specifically measuring a single nucleotide polymorphism, an attempt is often made to secure the specificity by designing allele-specific primers, but it is often difficult to secure complete specificity depending on the nucleotide sequence around the single nucleotide polymorphism as the subject. When a system for measuring the SMN1 gene for newborn screening application is developed, the analyte to be measured is a paper piece cut out of a dried blood spot in a filter paper, and thus considerable ingenuity is required for the elution of blood from the paper piece, elution of an interfering substance and the like.
In Non-Patent Document 1, the specificity to the SAM gene is secured by designing a fluorescently labeled LNA (Locked Nucleic Acid) probe to the 110th position of the two single nucleotide polymorphisms in intron 7 of the SMN2 gene instead of one in exon 7 and thus specifically inhibiting the amplification of the SMN2 gene.
In Non-Patent Document 2, a measurement method using the melting curve assay of the amplification product of PCR reaction which is performed using primers designed to flank the sixth nucleotide of exon 7 is reported. The method is not suitable for screening test because not only an amplification product of the SMN1 gene but also an amplification product of the SMN2 gene is generated and because the melting curves thus overlap each other and are difficult to assess.
In the method reported in Non-Patent Document 3, a part of the reaction solution of first PCR reaction performed using primers designed to flank the sixth nucleotide of exon 7 is used for second PCR reaction using short primers in which complementary nucleotides to the SMN1 gene and the SMN2 gene are located in the middle, and the amplification product is analyzed by electrophoresis. The method is a method which uses the principles of so-called nested-PCR, which is a method used when the specificity of the primers in the first reaction is insufficient. A major defect of the method is an increase in the risk of contamination to the environment caused by the scattering of the amplification product due to opening of the cover after the first PCR reaction. Moreover, the amplification product is detected as a band of the amplification product through electrophoresis, and thus the method is not suitable for screening test also in view of the measurement efficiency.
Non-Patent Document 4 reports a method for quantifying the SMN1 gene by real-time PCR reaction which is performed using primers designed to flank the sixth position of exon 7 and a fluorescent dye-modified probe which is complementary to the sixth position of exon 7. In the method, because an amplification product derived from the SMN2 gene is also generated at the same time, there is a concern that the specificity of the probe cannot be secured when the CNV (Copy Number Variation) of the SMN2 gene is high.
In Non-Patent Documents 5 and 6, although primers similar to those of the invention are designed and used, purified DNA is used as an analyte in both documents, and the methods are not suitable for screening test also in view of the measurement efficiency.
[Non-Patent Document 1] Clinical Chemistry, 61:2, 412-419, 2015
[Non-Patent Document 2] Clinical Chemistry, 58:6, 1033-1039, 2012
[Non-Patent Document 3] Kobe J. Med. Sci., 63:2, E37-40, 2017
[Non-Patent Document 4] Genet Med, 8:7, 428-437, 2006
[Non-Patent Document 5] Neurogenetics 8, 271-278, 2007
[Non-Patent Document 6] Am. J. Hum. Genet. 70, 358-368, 2002
An object of the invention is to provide a primer for detecting and quantifying homozygous deletion of the SMN1 gene, the deletion of which causes SMA, using a dried blood spot in a filter paper and a method related to specific detection/quantification of the SMN1 gene using the primer.
Although SMA has been considered as a mortal disease so far, a therapeutic agent has been developed recently, and treatment has been started in clinical sites. Thus, improvement of QOL is expected. In particular, symptoms of type I tend to become severe, and the treatment is desirably started at the earliest possible stage. In view of the request, a versatile and rapid detection/quantification system which can be applied to newborn screening and which is highly specific to the SMN1 gene is desired.
By designing and using a primer which is highly specific to the SMN1 gene and with which the reactivity to the SMN2 gene is extremely lower than the reactivity to the SMN1 gene in a method for detecting the SMN1 gene by direct real-time PCR using a dried blood spot in a filter paper, a method for detecting and quantifying the SMN1 gene which can determine whether the SMN1 gene is deleted or not has been established. The invention has been thus completed.
That is, the invention has the following structures.
<1>
A method for detecting the SMN1 gene in a dried blood spot in a filter paper by real-time PCR, including the steps of (A) to (D) below:
(A) a step of adding the dried blood spot in a filter paper to a PCR reaction tube;
(B) a step of adding a PCR reagent to the PCR reaction tube, wherein the PCR reagent contains at least a primer designed in a manner that the reactivity to the SMN2 gene is less than 1% of that to the SMN1 gene, a polymerase, dNTPs and an intercalator or a fluorescently labeled probe;
(C) a step of performing PCR reaction in the tube containing the PCR reagent and the dried blood spot in a filter paper; and
(D) a step of sequentially and optically detecting a target nucleic acid in the SMN1 gene amplified by the PCR reaction.
<2>
The detection method described in <1>, wherein the primer designed in a manner that the reactivity to the SMN2 gene is less than 1% of that to the SMN1 gene is one or more primers selected from the group consisting of the forward primer of (1) and the reverse primer of (2) below:
(1) a forward primer having any of the nucleotide sequences of SEQ ID NOs: 1 to 9; and
(2) a reverse primer having any of the nucleotide sequences of SEQ ID NOs: 16 to 21.
<3>
The detection method described in <1>or <2>, wherein the dried blood spot in a filter paper is a circular punched piece with a diameter of 1.2 mm to 2.0 mm or a punched piece containing whole blood in an amount of 0.95 v/v % to 6.6 v/v % based on the total amount of the reaction solution.
<4>
A primer for specifically detecting the SAM gene which is one or more primers selected from the group consisting of the forward primer of (1) and the reverse primer of (2) below:
(1) a forward primer having any of the nucleotide sequences of SEQ ID NOs: 1 to 9; and
(2) a reverse primer having any of the nucleotide sequences of SEQ ID NOs: 16 to 21.
<5>
A method for weakening the reactivity to the SMN2 gene in a method for detecting the SMN1 gene in a dried blood spot in a filter paper by real-time PCR which uses one or more primers selected from the group consisting of the forward primer of (1) and the reverse primer of (2) below:
(1) a forward primer having any of the nucleotide sequences of SEQ ID NOs: 1 to 9; and
(2) a reverse primer having any of the nucleotide sequences of SEQ ID NOs: 16 to 21.
According to the invention, the provision of a primer which amplifies a specific region of the SMN1 gene in real-time PCR using a dried blood spot in a filter paper and which does not easily amplify the SMN2 gene and has low reactivity has been enabled. Moreover, using the primer, the provision of a method for specifically detecting or quantifying the SMN1 gene in a dried blood spot in a filter paper by real-time PCR has been enabled.
Accordingly, a rapid detection/quantification system for the SMN1 gene that can be applied to newborn screening in which the symptoms tend to become severe and in which the treatment is desirably started at an early stage can be provided.
The SMN1 gene-specific primer of the invention is a primer designed in a manner that the primer specifically amplifies the SMN1 gene and does not easily amplify the SMN2 gene. That is, the primer is a primer designed in a manner that the reactivity to the SMN2 gene is less than 1% of that to the SAM gene. The reactivity is determined as follows. Assuming that the reactivity is 100% when the Cq values are the same in the case where the copy numbers of the SMN1 gene and the SMN2 gene per reaction are the same, the reactivity is 10% when the Cq values are the same in the case where the copy number of the SMN2 gene per reaction is 10 times higher than that of the SMN1 gene, and the reactivity is 1% when the Cq values are the same in the case where the copy number is 100 times higher. Here, when the Cq value of the SMN1 gene is smaller, the reactivity is determined to be less than 1%. In the Examples described below, of the combinations of the conditions for the primers and the amplification elongation temperature, when the ΔCq value which was obtained by subtracting the Cq value of the SMN2 gene 10,000 copy/reaction from the Cq value of the SAM gene 100 copy/reaction was less than −0.1, the reactivity was determined to be less than 1%.
It has been also found that, when PCR reaction is performed using the primer of the invention, the reactivity to the SMN2 gene further weakens in the case where a dried blood spot in a filter paper is used as an analyte.
The forward primer which is specific to the SMN1 gene of the invention may be specifically a primer having any of the nucleotide sequences of SEQ ID NO 9. The forward primers are designed to contain C at the sixth position of exon 7 of the SMN1 gene at the 3′ end. The forward primers have a length of 22 to 30 bases in succession from C at the sixth position toward the 5′ end. The successive bases are preferably identical to the corresponding nucleotide sequence in the SMN1 gene, but a primer having a difference by one or some bases which do not hinder the amplification of the target nucleic acid is also included in the scope of the primer of the invention.
The reverse primer which is specific to the SMN1 gene of the invention may be a primer having any of the nucleotide sequences of SEQ ID NOs: 16 to 21. The reverse primers are designed to contain the complementary sequence to the sixth position of exon 7 of the SMN1 gene at the 3′ end of the reverse primers and have a length of 20 to 25 bases. The successive bases are preferably identical to the corresponding complementary strand of the SMN1 gene, but a primer having a difference by one or some bases which do not hinder the amplification of the target nucleic acid is also included in the scope of the primer of the invention.
As the primer of the invention, either of the forward primer which is specific to the SMN1 gene and the reverse primer which is specific to the SMN1 gene may be used, and the reverse primer and the forward primer used as a set are desirably 20 bp or more apart in the case of real-time PCR considering the necessity for designing a fluorescently labeled probe in the region between the primers.
The reverse primer used with the forward primer which is specific to the SMN1 gene of the invention as a set may be the reverse primer which is specific to the SMN1 gene of the invention, or a primer containing a complementary sequence to a nucleotide sequence which is identical to a part of the exon 7 or intron 7 region as long as the forward and reverse primers are 20 bp or more apart.
The forward primer used with the reverse primer which is specific to the SMN1 gene of the invention as a set may be the forward primer which is specific to the SMN1 gene of the invention or a primer containing a nucleotide sequence which is identical to a part of the intron 6 region.
When PCR is performed using the forward primer which is specific to the SMN1 gene or the reverse primer which is specific to the SMN1 gene of the invention, nucleic acid containing C at the sixth position of exon 7 of the SMN1 gene is amplified. On the other hand, because the sixth position of exon 7 of the corresponding nucleic acid of the SMN2 gene is T, which is not recognized by the 3′ end of the forward primer which is specific to the SMN1 gene or the reverse primer which is specific to the SMN1 gene of the invention, the amplification reaction by the polymerase is not caused easily.
Moreover, when a dried blood spot in a filter paper is used as an analyte, the amplification reaction of the SMN2 gene becomes further difficult, and specific detection of the SMN1 gene is thus enabled.
In this manner, when a dried blood spot in a filter paper is used as an analyte for PCR using at least one kind of the forward primer which is specific to the SMN1 gene and the reverse primer which is specific to the SMN1 gene of the invention, the effects can be exerted more. That is, because the region in exon 7 of the SMN1 gene can be amplified specifically and because the region in the SMN2 gene is hardly amplified, the SMN1 gene can be detected or quantified specifically. The amplified nucleic acid can be qualitatively or quantitatively analyzed by electrophoresis, real-time PCR or the like.
It has been demonstrated in the Examples described below that the reactivity to the SMN2 gene is less than 1% of that to the SMN1 gene when PCR is performed using the forward primer which is specific to the SMN1 gene or the reverse primer which is specific to the SMN1 gene of the invention.
The real-time PCR method generally means a method for sequentially monitoring the process of generation of an amplification product in PCR. In the invention, detection by real-time PCR means detection of an amplified target nucleic acid in the SMN1 gene (also simply referred to as an amplification product below) by optical means after the PCR reaction. Here, the amplification product may be detected, for example, at the time of completion of the PCR reaction or after the completion or may be detected simultaneously during the PCR reaction step. In the case of simultaneous detection, the amplification product can be detected, for example, sequentially. The sequential detection (monitoring) may be, for example, continuous or noncontinuous (intermittent) detection.
The temperature changes of the steps in the PCR reaction may be automatically controlled using, for example, a thermal cycler or the like. The amplification product generated by the PCR reaction can be detected, for example, by detecting the fluorescence intensity generated from the amplification product. The fluorescence detection is not particularly restricted but is the conventionally known intercalator method, the TaqMan (registered trademark) probe method, the hybridization method, the cycling probe method or the like.
The fluorescence intensity can be detected, for example, with a fluorometer. Moreover, in general, an apparatus which has both a PCR reaction unit (for example, a thermal cycler) and an optical unit (for example, a fluorometer) is used. Specific examples include commercial SMartCycler (product name, manufactured by Takara Bio Inc.), LightCycler (product name, manufactured by Roche Diagnostics), ABI PRISM7000 (product name, manufactured by Applied Biosystems) and the like.
The method for quantifying the SMN1 gene of the invention is a method of generating an amplification product complementary to a target nucleic acid in the SMN1 gene in a sample, detecting the amplification product by optical means and quantifying the amplification product. By counting the PCR cycle number at which the amount of the amplification product has reached a certain amount, the target nucleic acid contained in the sample can be quantified in the method. Moreover, as in the Examples described below, the quantification can be conducted by calculating the copy number of 1 μL of whole blood in the sample from a calibration curve of the Cq values calculated from the standards.
The PCR reagent used in the invention contains at least a set of primers, a polymerase, dNTPs (deoxynucleoside triphosphates), an intercalator or a fluorescently labeled probe. The reagent also typically contains a buffer. The buffer is not particularly limited as long as the buffer has the function of inhibiting the activities of substances which inhibit the DNA amplification reaction, such as positively charged substances (certain kinds of protein and the like) and negatively charged substances (certain kinds of saccharide, dyes and the like), in the body fluid of a living thing. Examples of commercial buffers include Ampdirect, Ampdirect plus (both manufactured by Shimadzu Corporation) and the like. The amount of the PCR reagent used in the invention added to a reaction tube is 20 to 50 μL.
The sample used in the invention is preferably blood in a filter paper that is obtained by blotting blood on the filter paper and then drying the blood, which is called a dried blood spot in a filter paper. The dried blood spot in a filter paper is taken out using a punching device as a paper piece having the shape of the punching hole (punched piece). Examples of the dried blood spot in a filter paper used include blood on a filter paper collected from the heel of a newborn during newborn mass screening or the like, blood on a filter paper collected during simultaneous optional screening and the like, but the dried blood spot in a filter paper is not limited to the examples. Regarding the size of the punched piece that is cut out from the dried blood spot in a filter paper, a punched piece having a certain size is desirable because the amount of the contained blood should be in an appropriated range. The punched piece having a certain size is desirably a circular punched piece with a diameter of 1.2 to 2.0 mm, further desirably a circular punched piece with a diameter of 1.5 mm to 1.8 mm. The whole blood amount contained in the punched piece based on the total amount of the PCR reaction solution is desirably 0.95 v/v % to 6.6 v/v %, further desirably 1.4 v/v % to 5.2 v/v %. Here, the whole blood amount is indicated as the proportion which is obtained by adding a circular punched piece with a diameter of 1.2 to 2.0 mm or a circular punched piece with a diameter of 1.5 mm to 1.8 mm to 20 to 50 μL of a PCR reaction solution and dissolving the blood and which is calculated based on the actual value (when 30 μL of whole blood was added to a filter paper before cutting out a punched piece and dried, the diameter of the created circular blood portion was 9.5 mm).
The tube used in the invention is a tube for PCR reaction and has a structure into which a punched piece of the filter paper with blood can be smoothly inserted and which can be sealed with a cap. In a suitable shape, the opening at the upper part of the tube is a circle (for example, an inside diameter of around 2.5 mm to 10 mm), and the bottom is narrower than the opening at the upper part. An inverted cone shape or the like is preferable.
The volume of the tube may be a volume to which the PCR reaction reagent can be added and which can sufficiently hold the reaction solution even with the temperature changes during the PCR reaction, and the tube preferably has a volume of 0.1 mL to 0.3 mL, further preferably a volume of 0.15 mL to 0.25 mL, most preferably a volume of 0.2 mL.
The PCR reaction tube used in the invention is preferably a 96-well plate for PCR reaction in which 96 tubes are connected or one in an eight-tube strip in which eight tubes are connected, and as commercial products, those sold with a name 96-well PCR plate, PCR eight-tube strip or the like can be used. Commercial products include LightCycler (registered trademark) 480 Multiwell Plate 96 (Roche, Inc.), 96-Well PCR Plate, Flat Top, Low Profile, Natural, Polypropylene, UltraFlux (Scientific Specialties, Inc.), Eppendorf PCR plate 96, skirtless, 150 μL, colorless (Eppendorf), PCR plate 96-well simplate 0.1 mL natural (BM Equipment Co., Ltd.), LightCycler 8-Tube Strips (Roche, Inc.) and the like.
The material of such a reaction tube desirably causes little contamination of the reaction solution and is stiff so that the shape does not change even with the changes in the internal pressure due to the temperature changes during the PCR reaction, and the tube is made of polypropylene, for example.
The kit of the invention is a kit for specifically detecting the SMN1 gene by real-time PCR and includes one or more primers selected from the group consisting of the forward primer of (1) and the reverse primer of (2) below:
(1) a forward primer having any of the nucleotide sequences of SEQ ID NOs: 1 to 9; and
(2) a reverse primer having any of the nucleotide sequences of SEQ ID NOs: 16 to 21.
In addition, the kit can include a reverse primer or a forward primer which is used as a set with the primer. Moreover, the kit can also include a probe or a reagent or a container used for PCR or real-time PCR.
The present invention is explained in detail below by Examples, but the invention is not limited to the Examples below.
The present Examples are examples which compared the reactivities of the designed primers to the SMN1 gene and SMN2 gene sequences.
(a-1) SMN1 Gene Amplification Forward Primers
Forward primers for the SMN1 gene amplification (Table 1; SEQ ID NOs: 1 to 9) and a common reverse primer (Table 1; SEQ ID NO: 10) were synthesized by Sigma-Aldrich Co. LLC and used.
(a-2) Plasmids
As templates of the PCR reaction, plasmids having a partial sequence shown below which included exon 7 of the SMN1 gene or the SMN2 gene and which was incorporated in a vector were synthesized by Eurofins Scientific SE and used. The underlined part of SEQ ID NO: 11 below shows the sequence of exon 7 (54 bp) of the SMN1 gene, where the upstream is a partial sequence of intron 6, and the downstream shows a partial sequence of intron 7. The underlined part of SEQ ID NO: 12 shows the sequence of exon 7 (54 bp) of the SMN2 gene, where the upstream is a partial sequence of intron 6, and the downstream shows a partial sequence of intron 7.
The sixth position of exon 7 of the SMN1 gene is C, while the sixth position of exon 7 of the SMN2 gene is T.
TTCAGACAAAATCAAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAAGGA
TTTAGACAAAATCAAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAAGGA
The composition of the PCR reagent is shown below.
SMN1 gene plasmid (final concentration) 100,000 copy/reaction, 10,000 copy/reaction, 1,000 copy/reaction, 100 copy/reaction
SMN2 gene plasmid (final concentration) 100,000 copy/reaction, 10,000 copy/reaction
(e-1) Measurement Method
The measurement was made by the following procedures.
The results are shown in Table 2. Of the combinations of the conditions for the primers and the amplification elongation temperature, there were 11 combinations in which the reactivity to the SMN2 gene was less than 1% of that to the
(f-1) SMN1 Gene Amplification Reverse Primers
Reverse primers for the SMN1 gene amplification (Table 3; SEQ ID NOs: 14 to 22) and a common forward primer (Table 3; SEQ ID NO: 13) were synthesized by Sigma-Aldrich Co. LLC and used.
(f-2) Plasmids
The same plasmids as those in (a-2) above were used.
The composition of the PCR reagent is shown below.
The same plasmid dilution series as those in (c) above were used.
The reaction was performed under the same conditions as those in (d) above.
(j-1) Measurement Method
The measurement was made by the following procedures.
The results are shown in Table 4. Of the combinations of the conditions for the primers and the amplification elongation temperature, there were 8 combinations in which the reactivity to the SMN2 gene was less than 1% of that to the SMN1 gene, that is, there were 8 combinations that satisfied the ΔCq value of less than -0.1, where the ΔCq value was obtained by subtracting the Cq value of the SMN2 gene 10,000 copy/reaction from the Cq value of the SMN1 gene 100 copy/reaction. The reverse primers of SEQ ID NOs: 16 to 21 were applicable.
(a-1) SMN1 Gene Amplification Primers
As the primers for the SMN1 amplification, the following primers were synthesized by Sigma-Aldrich Co. LLC and used.
SMN1-specific forward primer; SEQ ID NO: 6 in Table 1 above
SMN1 common reverse primer; SEQ ID NO: 10 in Table 1 above
(a-2) SMN1 Detection Probe
As the probe for observing the PCR amplification of SMN1, the following detection probe which was fluorescently labeled was synthesized and produced by Primetech Corporation and used.
The composition of the PCR reagent is shown below. PCR buffer (Ampdirect Plus; Shimadzu Corporation)
A plasmid into which a partial sequence of SMN1 (SEQ ID NO: 11) was incorporated was added to the PCR reagent of (b) above, and PCR reagents containing the standards below (dilution series; STD1 to 4) were prepared. The values in the brackets are the copy numbers of the gene per one PCR reaction. The reagents were used in the solution state without adding to a dried blood spot in a filter paper. STD1 (SMN1 100,000 copy/reaction), STD2 (SMN1 10,000 copy/reaction), STD3
(SMN1 1000 copy/reaction), STD4 (SMN1 100 copy/reaction)
A plasmid into which a partial sequence of SMN2 (SEQ ID NO: 12) was incorporated was added to the PCR reagent of (b) above at 50,000 copy/reaction, and a PCR reagent for SMN2 cross test was thus prepared.
Blood obtained by mixing a human erythrocyte fraction from which leukocytes were removed and human plasma (EDTA) at a ratio of 6:4 in a volume of 40 μL was blotted on a filter paper for blood collection (Advantec) and directly dried, and the blood obtained was used as a DNA-free dried blood spot in a filter paper. This means that the dried blood spot in a filter paper did not contain SMN1 and SMN2.
(g-1) Measurement Method
The measurement was made by the following procedures.
It was observed that the amplification is excellent to SMN1 100 copy/reaction.
(ii) The parts of the amplification reaction curves of the PCR reagent for SMN2 cross test at 25 to 40 cycles are shown in
Interestingly, it was observed that the rising of the amplification delayed by Cq value of around 1 (the dotted line in the figure) when the punched piece of the DNA-free dried blood spot in a filter paper coexisted, as compared to the case where the empty punched piece (the punched piece containing no blood) coexisted (the solid line in the figure). This means that, under the conditions, the cross reaction to SMN2, in terms of the copy number, decreased by about 50%. That is, it was found that, when a primer designed in a manner that the reactivity to the SMN2 gene is less than 1% of that to the SMN1 gene in the invention is applied to a case where a dried blood spot in a filter paper is used as an analyte, the reactivity to the SMN2 gene weakens. This means that it was found that, when PCR reaction is performed using the primer of the invention, the cross reaction to the SMN2 gene is reduced more in the presence of a punched piece of a dried blood spot in a filter paper in the reaction system.
Therefore, the invention leads to a reduction in the risk of overlooking a SMA patient having homozygous deletion of SMN1 (false negative) in newborn screening test.
Here, when a test was conducted in the same manner also regarding SMN1, inhibition of the amplification by a dried blood spot in a filter paper was not observed (the results are not shown in the figures). Therefore, it was found that the phenomenon of the delayed rising of the amplification due to the coexistence of a dried blood spot in a filter paper is specific to the amplification reaction of the SMN2 gene. Thus, in other words, the invention of the present application is a method for weakening the reactivity to the SMN2 gene using a specific primer in a method for detecting the SMN1 gene in a dried blood spot in a filter paper by real-time PCR.
According to the invention, the provision of a method for specifically detecting or quantifying the SMN1 gene in a dried blood spot in a filter paper by real-time PCR has been enabled using the specific primer of the invention. Therefore, a rapid detection/quantification system for the SMN1 gene which can be applied to newborn screening in which the symptoms tend to become severe and in which the treatment is desirably started at an early stage can be provided.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2019-137633 | Jul 2019 | JP | national |
| 2020-054242 | Mar 2020 | JP | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/JP2020/028374 | 7/22/2020 | WO |
